Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 2;13(1):e066623.
doi: 10.1136/bmjopen-2022-066623.

Fibrinolytic therapy in patients with COVID-19 and ARDS: protocol for a systematic review and meta-analysis

Felicio Savioli  1   2 , Lucas Ribeiro Dos Santos  2 , Marcio Luis Duarte  2 , Andreia Cristina Feitosa do Carmo  2 , Aecio Gois  2 , Luis Nakano  2 , Fernando Jose Da Silva Ramos  3 , Laerte Pastore  3 , Eduardo Leite Vieira Costa  3   4   5
Affiliations

Fibrinolytic therapy in patients with COVID-19 and ARDS: protocol for a systematic review and meta-analysis

Felicio Savioli et al. BMJ Open. .

Abstract

Introduction: In COVID-19-related acute respiratory distress syndrome (ARDS), the clot play a role in gas exchange abnormalities. Fibrinolytic therapy can improve alveolar ventilation by restoring blood flow. In this systematic review and meta-analysis protocol, we aim to assess the safety and efficacy of fibrinolytic therapy in such a population.

Methods: We will perform a systematic search in MEDLINE, EMBASE, Cochrane CENTRAL and LILACS databases without language restrictions for relevant randomised controlled trials (RCTs) and quasi-RCTs. Two review authors will independently perform data extraction and quality assessments of data from included studies. In case of divergence, a third author will be contacted. The Cochrane handbook will be used for guidance. If the results are not appropriate for a meta-analysis, a descriptive analysis will be performed.

Discussion: This systematic review and meta-analysis protocol will provide current evidence about the safety and efficacy of fibrinolytic therapy in patients with COVID-19 and ARDS. These findings will provide if fibrinolytic therapy might be an option for a desperate clinical setting, where all medical efforts have been used.

Prospero registration number: PROSPERO CRD42020187482.

Ethics and dissemination: Ethics committee approval is not necessary. We intend to update the public registry, report any protocol amendments and publish the results in a widely accessible journal.

Keywords: Adult intensive & critical care; Anticoagulation; COVID-19; RESPIRATORY MEDICINE (see Thoracic Medicine).

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

References

    1. Zhu N, Zhang D, Wang W, et al. . A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727–33. 10.1056/NEJMoa2001017 - DOI - PMC - PubMed
    1. Huang C, Wang Y, Li X, et al. . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 2020;395:497–506. 10.1016/S0140-6736(20)30183-5 - DOI - PMC - PubMed
    1. Marini JJ, Gattinoni L. Management of COVID-19 respiratory distress. JAMA 2020;323:2329. 10.1001/jama.2020.6825 - DOI - PubMed
    1. Whyte CS, Morrow GB, Mitchell JL, et al. . Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19. J Thromb Haemost 2020;18:1548–55. 10.1111/jth.14872 - DOI - PMC - PubMed
    1. Liu C, Ma Y, Su Z, et al. . Meta-Analysis of preclinical studies of fibrinolytic therapy for acute lung injury. Front Immunol 2018;9:9. 10.3389/fimmu.2018.01898 - DOI - PMC - PubMed